1. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

   • Vincent Launay-Vacher
   • Jean-Baptiste Rey
   • Mikael Daouphars

   Review 04 March 2008 Pages: 903 - 909

2. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand

   • Henriette Gourdeau
   • James B. McAlpine
   • Pierre Falardeau

   Original Article 11 July 2007 Pages: 911 - 921

   

3. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

   • Jon Patterson
   • Vito J. Palombella
   • Emmanuel Normant

   Original Article 12 July 2007 Pages: 923 - 932

   

4. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q₁₀, Niacin and Riboflavin

   • Srinivasan Yuvaraj
   • Vummidi Giridhar Premkumar
   • Panchanatham Sachdanandam

   Original Article 01 August 2007 Pages: 933 - 941

   

5. Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells

   • Rui Wang
   • Fang Lin
   • Hui-Zhong Zhang

   Original Article 26 July 2007 Pages: 943 - 952

   

6. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity

   • Fanying Meng
   • Xiaohong Cai
   • Charles P. Hart

   Original Article 18 July 2007 Pages: 953 - 963

   

7. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression

   • Andrea Rocca
   • Giuseppe Viale
   • Marco Colleoni

   Original Article 18 July 2007 Pages: 965 - 971

8. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin

   • Hirokazu Kawano
   • Shintaro Komaba
   • Yasufumi Kaneda

   Original Article 26 July 2007 Pages: 973 - 978

   

9. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells

   • Jianli Chen
   • Mahesha Adikari
   • Henry Simpkins

   Original Article 28 July 2007 Pages: 979 - 987

   

10. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group

    • Norikazu Masuda
    • Tetsuya Taguchi
    • Kinki Breast Cancer Study Group (KBCSG)

    Original Article 20 July 2007 Pages: 989 - 995

11. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors

    • Jianjun Lu
    • John K. Jackson
    • Helen M. Burt

    Original Article 15 August 2007 Pages: 997 - 1005

    

12. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line

    • Teresa L. Serafim
    • Paulo J. Oliveira
    • Jon Holy

    Original Article 28 July 2007 Pages: 1007 - 1018

    

13. A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

    • E. Gabriela Chiorean
    • Tomislav Dragovich
    • Patrick J. Loehrer

    Original Article 28 July 2007 Pages: 1019 - 1026

    

14. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples

    • Erwin R. Boghaert
    • Kiran M. Khandke
    • Nitin K. Damle

    Original Article 01 August 2007 Pages: 1027 - 1035

    

15. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats

    • Pengfei Song
    • Fei Ma
    • Charles R. Yates

    Original Article 01 September 2007 Pages: 1037 - 1044

    

16. Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth

    • Shirley Cruz Lio
    • Jessica Johnson
    • Mark L. Richards

    Original Article 10 August 2007 Pages: 1045 - 1058

    

17. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study

    • Michael D. Prados
    • W. K. A. Yung
    • John Kuhn

    Clinical Trial Report 11 August 2007 Pages: 1059 - 1067

18. A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

    • Robert J. Amato
    • Muhammad Khan

    Clinical Trial Report 14 August 2007 Pages: 1069 - 1073

19. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

    • F. J. P. Hoebers
    • D. Pluim
    • A. C. Begg

    Short Communication Open access 18 July 2007 Pages: 1075 - 1081

    

20. Dermatitis after suspected imatinib–levothyroxine interaction in a patient with gastrointestinal stromal tumor

    • Evangelos Cholongitas
    • Chrysoula Pipili
    • Maria Dasenaki

    Letter to the Editor 07 August 2007 Pages: 1083 - 1084